Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
Author(s) -
Shota Fukuoka,
Hiroki Hara,
Naoki Takahashi,
Takashi Kojima,
Akihito Kawazoe,
Masako Asayama,
Takako Yoshii,
Daisuke Kotani,
Hitomi Tamura,
Yuichi Mikamoto,
Nami Hirano,
Masashi Wakabayashi,
Shogo Nomura,
Akihiro Sato,
Takeshi Kuwata,
Yosuke Togashi,
Hiroyoshi Nishikawa,
Kohei Shitara
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.03296
Subject(s) - medicine , regorafenib , nivolumab , colorectal cancer , oncology , open label , cancer , clinical trial , immunotherapy
This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom